Title:Naphthofuran Derivative BF4, a New Potent SIRT1 Activator, Regulates
Lipid Metabolism in 3T3-L1 Adipocytes via the SIRT1-AMPK Pathway
Volume: 19
Issue: 9
Author(s): Jian Gao, Fan Li, Ye Huang, Shihao Li and Qisi Lin*
Affiliation:
- Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, Jiangsu
221004, China
Keywords:
Obesity, SIRT1 activator, BF4, lipid metabolism, SIRT1/AMPK pathway, C/EBPβ, PPARγ.
Abstract:
Aim: Our previously reported naphthofuran derivative BF4, identified as a potent silent
information regulator 1 (SIRT1) activator, could alleviate high glucose stimulating apoptosis and
inflammation response in human renal tubular epithelial (HK-2) cells.
Introduction: In this study, the underlying effects of BF4 on lipid metabolism in 3T3-L1 adipocytes
were investigated.
Methods: The effects of BF4 on pre-adipocyte differentiation and adipocyte lipolysis were studied
using oil red O staining and quantitative glycerol and triglyceride content assay kits. Moreover, the
molecular mechanism of BF4 on adipogenesis and lipid metabolism in 3T3-L1 adipocytes was investigated
by real-time quantitative PCR and Western blotting analysis.
Results: We found that compound BF4 significantly decreased adipogenesis and lipid accumulation
and inhibited the differentiation of 3T3-L1 pre-adipocytes into adipocytes. Moreover, compound
BF4 decreased the expressions of several key regulators in adipocyte differentiation, including
C/EBPβ and PPARγ, and their downstream lipogenesis targets via the activation of the SIRT1/
AMPK pathway.
Conclusion: Our results demonstrated that the novel SIRT1 activator BF4 might be a potent candidate
for regulating lipid metabolism.